https://www.selleckchem.com/products/tween-80.html Lung cancer is a heterogeneous disease, and the availability of comprehensive genomic profiling has allowed for the characterization of its molecular subtypes. This has increased the ability to deliver "personalized medicines" by tailoring therapies to target driver mutations in a patient's cancer. The development of targeted therapies for non-small cell lung cancer (NSCLC) has helped define the era of precision medicine throughout oncology. This article aims to contextualize recent research and provide an updated summary of targeted therapies available for patients with NSCLC. With practitioners and clinical researchers in mind, we note standard of care therapies, important approvals, practice guidelines, and treatments in development. The first section discusses mutations in the epidermal growth factor receptor (EGFR) gene, and the second section examines rearrangements in the anaplastic lymphoma kinase (ALK) and ROS1 fusions. Finally, we explore the rarer molecular alterations in BRAF, RET, MET, HER2, and KRAS. Given the many available therapies, it is important to understand the molecular alterations in NSCLC, and how to target them.Congenital prosopagnosia (CP) is a life-long impairment in face recognition that occurs in the absence of any known brain damage. It is still unclear whether this disorder is related to a visual deficit, or to an impairment in encoding, maintaining or retrieving a face from memory. We tested CPs and matched neurotypical controls using a delayed estimation task in which a target face was shown either upright or inverted. Participants were asked to select the target face out of a cyclic space of morphed faces that could either resemble the target face, or not. The inclusion of upright and inverted faces enabled to examine the extent of the face inversion effect, a well-known face specific effect often associated with holistic processing. To enable disentangling visual from mnemonic pro